Shares of Indaptus Therapeutics (Nasdaq: INDP) are rallying premarket after news that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the company’s platform technology.
A notice of allowance is a letter of notification from the US Patent and Trademark Office that says a mark has got through the opposition period after publication in the Official Gazette and has been allowed. However, it does not mean the trademark has been registered yet.
Indaptus’ patent is titled, “Methods of Treatment of Infections Using Bacteria.” It provides protection for applying the company’s platform technology alone and in combination with standards of care for treating and inhibiting hepatitis B virus (HBV) and human immunodeficiency virus (HIV) infections.
Ready to put what you’ve learned into practice?
Try IG’s platform with £10,000 in virtual funds and practise trading
without putting your own money at risk.
Try IG with a demo account →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Learn the markets with IG Academy
Build your knowledge with IG Academy educational content, then use a
demo account to practise what you’ve learned on the IG platform.
Explore IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
See how trading works before risking real money
IG’s demo gives you access to thousands of markets and £10,000 in
virtual funds, so you can explore the platform and test your ideas first.
Open an IG demo →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Turn trading theory into practical experience
Learn with IG Academy, explore charts and market tools, and practise
strategies in a simulated trading environment before going live.
Start practising with IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
Ready to take your learning further?
IG combines market education, analysis and an established trading platform,
giving you the tools to keep learning as you develop your trading skills.
Discover IG →
Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 69% of retail investor accounts lose money when trading spread bets and CFDs with this provider.
“We are delighted to expand our growing patent estate and this notice of allowance provides further validation of the novel approach of our Indaptus platform technology as it relates to viral infections,” said Dr Michael Newman, Founder and Chief Scientific Officer of Indaptus Therapeutics.
Premarket, Indaptus Therapeutics shares are up 38.61% at $9.80, erasing September’s losses.
Should You Invest in Indaptus Therapeutics Shares?
One of the most frequently asked questions we receive is, “what stocks are best to buy right now?” It’s a wide-ranging question, but one that we have answered… Our AskTraders stock analysts regularly review the market and compile a list of which companies you should be adding to your portfolio, including short and longer-term positions. Here are the best stocks to buy right now
